CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
慢性淋巴细胞白血病的细胞治疗：移植与嵌合抗原受体 (CAR)-T 细胞
英文原题：Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.
查看英文原题
Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
慢性淋巴细胞白血病（CLL）治疗已取得显著进展，其中许多进展源于新药研发，因此高危CLL的定义也在变化。尽管如此，现有疗法仍很少能治愈CLL。随着治疗格局不断演变，目前正在评估或重新评估两类CLL细胞疗法：造血细胞移植和嵌合抗原受体（CAR）T细胞。本综述结合CLL治疗领域的变化，讨论这些细胞疗法的潜在作用、作用机制，以及哪些患者可能适合接受细胞治疗。
展开英文摘要原文
There is substantial progress in the therapy of chronic lymphocytic leukaemia (CLL), much of it the result of new drug development. As such the definition of high-risk CLL is changing. Nevertheless, few persons with CLL are cured with current therapy. Two types of cell therapies of CLL are currently being evaluated or re-evaluated in the context of these advances: haematopoietic cell transplants and chimeric antigen receptor (CAR)-T-cells.
We discuss the potential role of these cell therapies in the context of the evolving therapy topography of CLL including how these therapies work and who, if anyone, is an appropriate candidate for cell therapy.
论文信息
- 作者
- Yang S、Huang X、Gale RP
- 第一作者单位
- Peking University Peoples Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.China
- 通讯作者单位
- Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom. Electronic address: robertpetergale@alumni.ucla.edu.United Kingdom
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Blood reviews2022 Jan
- 原文标识
- PubMed 34489116 · DOI 10.1016/j.blre.2021.100884